Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND Baricitinib, an oral, selective Janus kinase (JAK)1/JAK2 inhibitor, is being studied for moderate-to-severe atopic dermatitis (AD) in adults. OBJECTIVE To evaluate the efficacy and safety of baricitinib monotherapy in a North American Phase 3 trial (BREEZE-AD5/NCT03435081) of adults with moderate-to-severe AD who responded inadequately or were intolerant to topical therapy. METHODS Patients (N=440) were randomized 1:1:1 to once-daily placebo or baricitinib (1 mg or 2 mg). The primary endpoint was the proportion of patients achieving ≥75% reduction in the Eczema Area and Severity Index (EASI75) at Week 16. A key secondary endpoint was the proportion of patients achieving a validated Investigator Global Assessment for AD (vIGA-AD™) score of 0 (clear)/1(almost clear) with ≥2-point improvement. RESULTS At Week 16, the proportion of patients achieving EASI75 was 8%, 13%, and 30% (P <.001, 2 mg vs. placebo) and those with a vIGA-AD 0/1 were 5%, 13%, and 24% (P <.001, 2 mg vs. placebo), for placebo, baricitinib 1 mg, and 2 mg, respectively. Safety findings were similar to other baricitinib AD studies. LIMITATIONS Short-term clinical trial results may not be generalizable to real-world settings. CONCLUSION Baricitinib was efficacious for patients with moderate-to-severe AD with no new safety findings over 16 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bieber, T., Thyssen, J. P., Reich, K., Simpson, E. L., Katoh, N., Torrelo, A., De Bruin‐Weller, M., Thaci, D., Bissonnette, R., Gooderham, M., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16948 · Cited by 152
Self-citation
Cited by
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
JAK inhibitors in the treatment of atopic dermatitis
Chovatiya, R., & Paller, A. S. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.08.009 · Cited by 398
JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review
Huang, I.-H., Chung, W.-H., Wu, P.-C., & Chen, C.-B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1068260 · Cited by 329
Novel insights into atopic dermatitis
Schuler, C. F., Billi, A. C., Maverakis, E., Tsoi, L. C., & Gudjonsson, J. E. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.10.023 · Cited by 281
Self-citationDavis, D. M. R., Drucker, A. M., Alikhan, A., Bercovitch, L., Cohen, D. E., Darr, J. M., Eichenfield, L. F., Frazer-Green, L., Paller, A. S., Schwarzenberger, K., et al. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.08.102 · Cited by 265
Self-citation
Metadata
- Authors
- Simpson, E. L., Forman, S., Silverberg, J. I., Zirwas, M., Maverakis, E., Han, G., Guttman-Yassky, E., Marnell, D., Bissonnette, R., Waibel, J., Nunes, F. P., DeLozier, A. M., Angle, R., Gamalo, M., Holzwarth, K., Goldblum, O., Zhong, J., Janes, J., & Papp, K.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 85
- Issue
- 1
- Pages
- 62-70
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W3129325639
- Cited by
- 140
- References
- 1
- FWCI
- 19.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). https://app.cochat.ai/papers/10.1016/j.jaad.2021.02.028
- The paper
- Simpson, E. L., Forman, S., Silverberg, J. I., Zirwas, M., Maverakis, E., Han, G., Guttman-Yassky, E., Marnell, D., Bissonnette, R., Waibel, J., Nunes, F. P., DeLozier, A. M., Angle, R., Gamalo, M., Holzwarth, K., Goldblum, O., Zhong, J., Janes, J., & Papp, K. (2021). Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2021.02.028
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.